The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.

A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

The invention provides an econazole nitrate and thiourea medical patch for the treatment of nail and skin onychomycosis, achieving improved drug penetration, and thus allowing more drug to penetrate into the nail bed and reach the minimum inhibitory concentration.

Provided is a topical skin application sheet having high affinity for skin and having an excellent occlusive dressing therapy (ODT) effect and excellent stretchability. Provided are a laminated adhesive sheet for skin including a skin adhesion layer, a protective adhesion layer, and a highly stretchable support laminated in this order; and a laminated adhesive sheet for skin including a skin adhesion layer, an intermediate layer, a protective adhesion layer, and a highly stretchable support laminated in this order.

Dosing regimens for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval are disclosed.

Dosing regimens for transdermal delivery of hormones comprising a variable treatment cycle and a fixed rest interval are disclosed.

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.